Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jazz Pharma Plc
(NQ:
JAZZ
)
108.39
-0.25 (-0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharma Plc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
April 11, 2022
Syros Pharmaceuticals Inc (NASDAQ: SYRS)
Via
Benzinga
Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma
April 07, 2022
Via
Benzinga
Expert Ratings For Jazz Pharmaceuticals
April 06, 2022
Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
April 06, 2022
Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading.
Via
Benzinga
Why Axsome Therapeutics Stock Is Trading Higher
March 28, 2022
Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ).
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Upgrades
Via
Benzinga
Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio
March 28, 2022
Axsome Therapeutics Inc (NASDAQ: AXSM) has
Via
Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
March 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Jazz Pharmaceuticals's Return On Capital Employed Insights
March 03, 2022
According to data from Benzinga Pro, during Q4, Jazz Pharmaceuticals's (NASDAQ:JAZZ) reported sales totaled $896.73 million. Despite a 33.09% increase in earnings, the company...
Via
Benzinga
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma
March 03, 2022
The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant C...
Via
Benzinga
Expert Ratings For Jazz Pharmaceuticals
March 02, 2022
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results
March 01, 2022
Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharma...
Via
Benzinga
Jazz Pharmaceuticals: Q4 Earnings Insights
March 01, 2022
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
This Company's 18-Month CBD Stability Achievement Could Hint Towards Expansion Goals As It Plans To Release First Commercial UST System In 2022
February 10, 2022
Photo by Kindel Media from Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Does This Company's Recent CBD Breakthrough Earn It A Spot In The Guinness World Records?
February 04, 2022
Photo by CBD Infos on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
New Psychedelics ETF Launches On NYSE Arca
February 02, 2022
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...
Via
Benzinga
The "Cannabis 50" List For 2021 Is Out, Is Your Favorite Company On It?
January 28, 2022
MGO (Macias Gini and O’Connell LLP), a leader in accounting, tax, audit and advisory solutions for the cannabis and hemp industries has released its 3rd annual “Cannabis 50” list.
Via
Benzinga
Jim Cramer Shares His Thoughts On ArcBest, Ulta Beauty And More
January 27, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes ArcBest Corporation (NASDAQ:
Via
Benzinga
Zogenix Nabs $1.9 Billion Takeover As Epilepsy Drug Piques UCB Interest
January 19, 2022
The deal includes a CVS tied to Fintepla's next potential approval.
Via
Investor's Business Daily
Report: Global Cannabis Beverages Market Expected To Reach $2B By 2026
January 14, 2022
As the COVID-19 pandemic continues, the global market for cannabis beverages estimated at $799.8 million 2020, is projected to reach a revised...
Via
Benzinga
60 Biggest Movers From Yesterday
January 11, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...
Via
Benzinga
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
January 06, 2022
Via
AB Newswire
A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report
January 04, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year....
Via
Benzinga
5 Stocks To Watch For January 4, 2022
January 04, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on...
Via
Benzinga
Ten Biggest Weed Stories Of 2021: Big Pharma, Delta-8, Tech, Silicon Valley, MSOs, Politics And More
January 03, 2022
This article was originally published on WeedWeek and appears here with...
Via
Benzinga
5 Themes That Will Drive The Cannabis Sector Higher In 2022
December 31, 2021
2021 was a period of strong growth for the global cannabis market and we expect the cannabis sector to build on its success in 2022.
Via
Talk Markets
Jazz Pharmaceuticals Begins Enrollment For Clinical Trial To Evaluate JZP150 For Adults With PTSD
December 30, 2021
Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced Thursday that it has enrolled the first patient in its Phase 2 clinical trial evaluating the safety and...
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.